MedPath

Promoting Optimal Outcomes in Mood through Psychosocial Therapies for cancer patients: a randomised trial

Not Applicable
Completed
Conditions
Depression in cancer patients
Distress in cancer patients
Risk of depression in cancer patients
Mental Health - Depression
Cancer - Other cancer types
Registration Number
ACTRN12610000448044
Lead Sponsor
Jane Turner
Brief Summary

Patients who received the intervention did not experience a significant reduction in depression scores compared with patients in control groups. Patients with disease progression who received the intervention experienced significant benefits in unmet practical support needs including care and support, information and physical and daily living

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
467
Inclusion Criteria

Patients eligible for this study must have a diagnosis of cancer and be attending any of the participating clinical Sites for medical review or treatment.
Aged 18 years or over
Consecutive patients attending outpatient oncology clinics at each Site
Are currently receiving active treatment for cancer OR
Have completed active treatment within the previous 2 months OR
Have been diagnosed with recurrent/advanced cancer within the previous 2 months

Exclusion Criteria

Inability to speak and read English; Receiving current specialised psychological treatment from a psychologist, psychiatrist, or other trained counsellor; Currently taking antidepressant medication; Health status precludes ability to complete questionnaires and participate in up to four (4) psychosocial Intervention sessions, and follow-up at 10 weeks; Recruited in any previous Epoch of this study (ie patients can only participate during one Epoch)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in depression as measured by Hospital Anxiety and Depression Score (HADS)[Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67:362-370][Baseline and 10-week follow-up]
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath